GSK settles second Zantac case in a month in California amid slew of US litigation

Firm wishes to avoid ‘protracted litigation’ with confidential settlement | Counsel for GSK told Delaware judge in January that lawsuits are ‘way ahead of the science’.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

GSK presses court to deny Teva’s ‘skinny label’ petition

25 August 2022 Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

Generics

GSK responds to Teva’s ‘skinny’ label rehearing petition

9 December 2021 Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

GSK settles second Zantac case in a month in California amid slew of US litigation

More on this story

Editor's picks

Editor's picks

More features